tbuckley/cabot-search huggingface dataset:
腫瘍脈管構造標的化により安全で効率的な全身遺伝子治療のための自由カチオマのないポリプレックスミセル設置細胞内自己プロセシング機能性【Powered by NICT】
Authors: Chen Qixian, Osada Kensuke, Ge Zhishen, Uchida Satoshi, A Tockary Theofilus, Dirisala Anjaneyulu, Matsui Akitsugu, Toh Kazuko, M Takeda Kaori, Liu Xueying, Nomoto Takahiro, Ishii Tekihiko, Oba Makoto, Matsumoto Yu, Kataoka Kazunori
Journal: Biomaterials (2017)
Timing of Pregnancy and Survival in Women With Breast Cancer
Authors: Samer Al Hadidi
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Mild cognitive impairment in Parkinson’s disease: a distinct clinical entity?
Authors: Ming-Ching Wen, Ling Ling Chan, Louis C.S. Tan, Eng King Tan
Journal: Translational Neurodegeneration (2017)

Mild cognitive impairment in Parkinson's disease (PD-MCI) is a common clinical condition. Understanding its pathology and clinical features is important for early intervention before the onset of dementia. In the past, variable definitions and differences in neuropsychological batteries generated divergent results of the affected cognitive patterns.
Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida et al
Authors: Kavish J. Bhansing, Marieke H. van Rosmalen, Baziel G. van Engelen, Piet L. van Riel, Sigrid Pillen, Madelon C. Vonk
Journal: Arthritis & Rheumatology (2017)

We read with interest the article by Yoshida and colleagues on the ability of muscle ultrasound for detecting of fasciitis among patients with dermatomyositis (DM) in the early phase of their disease (1). The authors used power Doppler ultrasonography to assess inflammation and vascularity of the fascia of different muscles.

This article is protected by copyright. All rights reserved.
Synergistic chemopreventive effect of the Chinese medicinal herbs Scutellaria barbata and Oldenlandia diffusa on tumor progression and development in TRAMP mice and induction of Caspase 9 in LNCaP cells
Authors: Dinh Nguyen, Brian Wong, Irena Cabrera, Randy Hausted
Journal: Cancer Research (2008)

LB-325    Scutellaria barbata  (SB) and  Oldenlandia diffusa  (OD) have long been used in Chinese medicine to treat various cancers. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mimics heterogenic tumor progression in human prostate cancer. Histopathological examination and palpation were used to detect tumor progression and development in this model. Our previous data demonstrated that treatment with SB or OD could delay  in vivo  tumor development in TRAMP mice. Positive  in vitro  TUNEL assay results in TRAMP C-1 and human LNCaP cells also indicated significant apoptotic induction of SB or OD via DNA fragmentation and activation of caspase 9. In this study, the combined effect of these two herbs on TRAMP mice was investigated. Male mice (9 weeks of age) were randomized into two groups. Daily, the placebo group (n = 21) was given distilled water while the experimental groups were fed with SB (32 mg, n = 8), OD (32 mg, n = 9), and SB + OD (16 mg + 16 mg, n = 11), respectively. The extent of caspase 9 activation and necrosis of living LNCaP cells on chamber slides was also examined. 50 μl of distilled water was added to the control chamber while 50 μl of aqueous extract of SB + OD (0.5 + 0.5 mg/ml) was added in the experimental chambers for 2 and 8 hr separately. A specific carboxyfluorescein (FAM) labeled peptide fluoromethyl ketone (FMK) caspase inhibitor (FAM-Peptide-FMK) was used to detect the presence of caspases. Kaplan-Meier survival plots revealed significant synergistic effects of SB + OD on the inhibition of tumor development in TRAMP mice as revealed by palpation. Overall log rank results revealed that mice fed with SB + OD had a significant increase in survival time when compared to the placebo (P  in vivo  data demonstrated significant synergistic inhibitory effects of SB + OD on tumor progression and development in TRAMP mice. The complimentary  in vitro  data indicate these herbs might up-regulate the apoptotic pathway of cancer cells via the induction of the caspase 9 cascade suggesting their chemopreventive and treatment potential.
化学療法剤の腫瘍標的送達のための細菌プロトプラスト由来ナノベシクル【Powered by NICT】
Authors: Kim Oh Youn, Dinh Nhung Thi Hong, Park Hyun Taek, Choi Seng Jin, Hong Kahye, Gho Yong Song
Journal: Biomaterials (2017)
A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE).
Authors: Masatoshi Kudo, Michihisa Moriguchi, Kazushi Numata, Hisashi Hidaka, Hironori Tanaka, Masafumi Ikeda, Seiji Kawazoe, Shinichi Ohkawa, Yozo Sato, Takuji Okusaka
Journal: Journal of Clinical Oncology (2015)

4018 Background: An unmet medical need persists for patients (pts) with sorafenib-refractory advanced hepatocellular carcinoma (HCC). This study was conducted to evaluate the efficacy and safety of S-1 in pts with sorafenib-refractory advanced HCC. Methods: Japanese men and women (aged ≥ 20 years) with Child-Pugh (C-P) A or B liver function and disease progression with or intolerance to sorafenib were randomized in a 2:1 ratio. S-1 (80, 100, or 120 mg/day) or a placebo was administered orally, according to the body surface area on days 1–28 of a 42-day cycle until disease progression or unacceptable toxicities were observed. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), overall response rate (ORR), and safety. For a statistical consideration of the heterogeneous population with advanced HCC, we conducted the subgroup analysis. Results: A total of 334 pts were enrolled (S-1 = 223, placebo = 111). Patient characteristics were well balanced; median age, 70.0 years; C-P A liver function, 81.0%; vascular invasion, 17.7%; and extrahepatic metastasis, 53.8%. The median OS was 337.5 days with S-1 and 340.0 days with the placebo (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.67–1.10; P = 0.220). The median PFS were 80 and 42 days, respectively (HR, 0.60; 95% CI, 0.46–0.77; P < 0.001). ORRs were 5.4% and 0.9%, respectively (P = 0.068). In the subgroup analysis showed the efficacy of S-1 on OS was different depending on patient characteristics; C-P liver function, HR was 0.79 (C-P A) and 1.19 (C-P B); Tumor stage, HR was 2.08 (Stage I/II) and 0.79 (Stage III/IV). The main adverse events (AEs) with S-1 were anorexia, fatigue, elevated total bilirubin, and diarrhea. Most AEs were mild to moderate, and the study discontinuation rate due to AEs was 19.2% in S-1 pts. Conclusions: Although S-1 did not statistically extend OS compared to the placebo in pts with sorafenib-refractory advanced HCC, the subgroup analysis showed S-1 has potential to improve OS in the clinically-important population. The observed benefit in the outcomes of PFS and subgroup analysis warrant further investigation. Clinical trial information: JapicCTI-090920.
Taming the Flames: Targeting White Adipose Tissue Browning in Hypermetabolic Conditions
Authors: Abdikarim Abdullahi, Marc G Jeschke
Journal: Endocrine Reviews (2017)

In this era of increased obesity and diabetes prevalence, the browning of white adipose tissue (WAT) has emerged as a promising therapeutic target to induce weight loss and improve insulin sensitivity in this population. The browning process entails a shift in the WAT from primarily storing excess energy to the dissipation of energy as heat. However, this idealistic view of WAT browning being the savior of the metabolic syndrome has been criticized by studies in burn and cancer patients that have shown browning to be detrimental rather than beneficial. In fact, in the context of hypermetabolic states, the browning of WAT has presented with substantial clinical adverse outcomes related to cachexia, hepatic steatosis, and muscle catabolism. Therefore, the previous thought construct of understanding browning as an all-beneficial physiologic event has now been met with skepticism. In this review, we focus on current knowledge of browning of WAT and its adverse metabolic alterations during hypermetabolic states. We also discuss the regulators and signaling pathways involved in the browning process and their potential for being targeted by new or existing drugs to inhibit or alleviate browning, potentially leading to decreased hypermetabolism and improved clinical outcomes. Lastly, the imminent clinical applications of pharmacological agents are explored in the perspective of attenuating WAT browning and its associated adverse side effects reported in burn patients.
Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum
Authors: Marta Cossu, Lenny van Bon, Carlo Preti, Marzia Rossato, Lorenzo Beretta, Timothy R. D. J. Radstake
Journal: Arthritis & Rheumatology (2017)

Patients with definite systemic sclerosis (SSc) who lack fibrotic features can be stratified into an intermediate stage of disease severity between preclinical/early SSc (EaSSc) and fibrotic subsets (limited cutaneous SSc [lcSSc] and diffuse cutaneous SSc [dcSSc]). The aim of the present study was to molecularly characterize nonfibrotic SSc and EaSSc on the basis of a broad panel of serum markers of inflammation and tissue damage, in order to increase the knowledge of the pathophysiologic mechanisms underlying SSc progression before the development of fibrosis.An 88-plex immunoassay was performed in serum samples from a discovery cohort composed of 21 patients with EaSSc (meeting the LeRoy and Medsger criteria), 15 with nonfibrotic SSc (meeting the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria, without skin or lung fibrosis), and 11 healthy controls. Analyte concentrations that were consistently significantly different at the exploratory P value threshold of 0.1 were selected for replication analysis in a larger group composed of 47 patients with EaSSc, 48 with nonfibrotic SSc, and 43 healthy controls, as well as 51 patients with lcSSc and 35 with dcSSc. The value of the replicated molecules in predicting SSc progression (at a family-wise error rate of 0.05) was tested.Based on the results of the explorative analysis, 16 molecules were selected for testing in the replication set. The results showed that CXCL10, CXCL11, tumor necrosis factor receptor type II (TNFRII), and chitinase 3-like protein 1 levels were significantly increased in patients with EaSSc and those with nonfibrotic SSc as compared to healthy controls. The disease in patients with high concentrations of CXCL10 and TNFRII was also characterized by a faster rate of progression from EaSSc and from nonfibrotic SSc to worse disease stages.SSc patients with preclinical/early SSc and those with established, yet nonfibrotic, disease exhibit clear molecular alterations that are associated with faster rates of disease evolution. These data open novel avenues for disease interception in SSc.
Thymic Retention of CD4+CD25hi+FoxP3+ T Regulatory (Treg) Cells Is Responsible for Peripheral Treg Deficiency and Platelet and Megakaryocyte Destruction in Active Immune Thrombocytopenia (ITP)
Authors: John W. Semple, Simon Gebremeskel, Rukhsana Aslam, Heyu Ni, John Freedman
Journal: Blood (2011)
Erratum
Journal: Journal of the American Society of Nephrology (2003)

Two incorrect figures were published in the August 2003 issue of JASN (Figures 7A and 8 in Hubchak SC, Runyan CE, Kreisberg JI, Schnaper HW: Cytoskeletal rearrangement and signal transduction in TGF-β1-stimulated mesangial cell collagen accumulation. [ J Am Soc Nephrol 14: 1969–1980, 2003)][1].
脂肪組織工学応用のためのRGD ミメト酸マクロ多孔性発泡体の生物学的および機械的駆動設計【Powered by NICT】
Authors: Rossi Eleonora, Gerges Irini, Tocchio Alessandro, Tamplenizza Margherita, Aprile Paola, Recordati Camilla, Martello Federico, Martin Ivan, Milani Paolo, Lenardi Cristina
Journal: Biomaterials (2016)
Exploring Coronary Circulatory Response to Stenosis and Its Association With Invasive Physiologic Indexes Using Absolute Myocardial Blood Flow and Coronary Pressure
Authors: Joo Myung Lee, Doyeon Hwang, Jonghanne Park, Jinlong Zhang, Yaliang Tong, Chee Hae Kim, Ji-In Bang, Minseok Suh, Jin Chul Paeng, Gi Jeong Cheon, Bon-Kwon Koo
Journal: Circulation (2017)

Although invasive physiological assessment for coronary stenosis has become a standard practice to guide treatment strategy, coronary circulatory response and changes in invasive physiological indexes, according to different anatomic and hemodynamic lesion severity, have not been fully demonstrated in patients with coronary artery disease.One hundred fifteen patients with left anterior descending artery stenosis who underwent both 13N-ammonia positron emission tomography and invasive physiological measurement were analyzed. Myocardial blood flow (MBF) measured with positron emission tomography and invasively measured coronary pressures were used to calculate microvascular resistance and stenosis resistance.With progressive worsening of angiographic stenosis severity, both resting and hyperemic transstenotic pressure gradient and stenosis resistance increased (P<0.001 for all) and hyperemic MBF (P<0.001) and resting microvascular resistance (P=0.012) decreased. Resting MBF (P=0.383) and hyperemic microvascular resistance (P=0.431) were not changed and maintained stable. Both fractional flow reserve and instantaneous wave-free ratio decreased as angiographic stenosis severity, stenosis resistance, and transstenotic pressure gradient increased and hyperemic MBF decreased (all P<0.001). When the presence of myocardial ischemia was defined by both low hyperemic MBF and low coronary flow reserve, the diagnostic accuracy of fractional flow reserve and instantaneous wave-free ratio did not differ, regardless of cutoff values of hyperemic MBF and coronary flow reserve.This study demonstrated how the coronary circulation changes in response to increasing coronary stenosis severity using 13N-ammonium positron emission tomography-derived MBF and invasively measured pressure data. Currently used resting and hyperemic pressure-derived invasive physiological indexes have similar patterns of relationships to the different anatomic and hemodynamic lesion severities.URL: https://www.clinicaltrials.gov. Unique identifier: NCT01366404.
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in <i>EGFR</i>-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Authors: Jörg Felsberg, Bettina Hentschel, Kerstin Kaulich, Dorothee Gramatzki, Angela Zacher, Bastian Malzkorn, Marcel Kamp, Michael Sabel, Matthias Simon, Manfred Westphal, Gabriele Schackert, Jörg C. Tonn, Torsten Pietsch, Andreas von Deimling, Markus Loeffler, Guido Reifenberger, Michael Weller
Journal: Clinical Cancer Research (2017)

Purpose: Approximately 40% of all glioblastomas have amplified the EGFR gene, and about half of these tumors express the EGFRvIII variant. The prognostic role of EGFRvIII in EGFR-amplified glioblastoma patients and changes in EGFRvIII expression in recurrent versus primary glioblastomas remain controversial, but such data are highly relevant for EGFRvIII-targeted therapies.Experimental Design:EGFR-amplified glioblastomas from 106 patients were assessed for EGFRvIII positivity. Changes in EGFR amplification and EGFRvIII status from primary to recurrent glioblastomas were evaluated in 40 patients with EGFR-amplified tumors and 33 patients with EGFR-nonamplified tumors. EGFR single-nucleotide variants (SNV) were assessed in 27 patients. Data were correlated with outcome and validated in 150 glioblastoma patients from The Cancer Genome Atlas (TCGA) consortium.Results: Sixty of 106 EGFR-amplified glioblastomas were EGFRvIII-positive (56.6%). EGFRvIII positivity was not associated with different progression-free or overall survival. EGFRvIII status was unchanged at recurrence in 35 of 40 patients with EGFR-amplified primary tumors (87.5%). Four patients lost and one patient gained EGFRvIII positivity at recurrence. None of 33 EGFR-nonamplified glioblastomas acquired EGFR amplification or EGFRvIII at recurrence. EGFR SNVs were frequent in EGFR-amplified tumors, but were not linked to survival.Conclusions: EGFRvIII and EGFR SNVs are not prognostic in EGFR-amplified glioblastoma patients. EGFR amplification is retained in recurrent glioblastomas. Most EGFRvIII-positive glioblastomas maintain EGFRvIII positivity at recurrence. However, EGFRvIII expression may change in a subset of patients at recurrence, thus repeated biopsy with reassessment of EGFRvIII status is recommended for patients with recurrent glioblastoma to receive EGFRvIII-targeting agents. Clin Cancer Res; 23(22); 6846-55. ©2017 AACR.
Let me stop when it is done
Authors: D.A. Frater
Journal: Annals of Internal Medicine (2017)

Ad Libitum5 September 2017Let me stop when it is doneD.A. Frater, MDD.A. Frater, MDFrom Dallas, Texas.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-0424 Audio Reading - “Let me stop when it is done” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Let me stop when it is done," by D.A. Frater. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I remind myself at the onsetof compressions choosing hand this timeover machine and its less kindless yielding resuscitationsas squeezing air by Ambu-bagfeels more like releasing a giftlike a last wish emptiedinto lungs abandoned by breathNot too hard I remind the youngtrainee who pushes on her chestthe rocking motion needing clayor doughTry not to crack the ribsI say though our poor soul won't careunless things work out yet we willrespect the dead the more so whilethis hope still infects us Author, Article, and Disclosure InformationAffiliations: From Dallas, Texas.Current Author Address: D.A. Frater, MD; e-mail, [email protected]md. PreviousarticleNextarticle Advertisement Audio Reading - “Let me stop when it is done” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Let me stop when it is done," by D.A. Frater. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 5 September 2017Volume 167, Issue 5Page: 331KeywordsLungsResuscitationRibsThorax ePublished: 5 September 2017 Issue Published: 5 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
サイトカインの原形質膜を標的とした送達のための可能なDNAナノキャリア【Powered by NICT】
Authors: Sun Wujin, Ji Wenyan, Hu Quanyin, Yu Jicheng, Wang Chao, Qian Chenggen, Hochu Gabrielle, Gu Zhen
Journal: Biomaterials (2016)
Abstract 18987: Wavefront Progression of Necrosis During Myocardial Infarction Revisited: The Wave Expands From Endo to Epi as Well as From Center to Lateral Borders
Authors: Rebeca Lorca, Marta Jimenez-Blanco, Jose Manuel García-Ruiz, Gonzalo Pizarro, Rodrigo Fernández-Jiménez, Ana García-Álvarez, Leticia Fernández-Friera, Valentin Fuster, Borja Ibanez
Journal: Circulation (2015)

Background and purpose: The widely accepted wavefront theory of myocardial necrosis during acute coronary occlusion describes its progression as a wavefront from endo towards epicardium. The lateral affection of the myocardium would be predetermined by the location of the coronary occlusion. At the time this phenomenon was firstly described, advanced imaging technology was not available. Current cardiac magnetic resonance (CMR) is able to accurately characterize the necrosis progression in vivo. Methods: A total of 220 patients with reperfused anterior STEMI (METOCARD-CNIC trial population) were studied. All the patients underwent cine, T2-weighted and late gadolinium enhancement CMR at day 5-7 after STEMI. Endo- and epicardial contours of each LV short axis slice was traced, and each one was divided by 100 cords for analysis. Infarct size was characterized in its 2 dimensions: lateral (defined as the percentage of cords with enhancement in every slice) and transmural extension (percentage of enhancement within each cord, nested in the lateral extension). All slices were weighed according to their relative mass. We compared these parameters between the cardioprotected metoprolol group and the control group. Results: A strong lineal correlation between transmural and lateral infarct extension was observed (r: 0.88, p&lt;0.001). We found that despite the edema lateral extension was larger than the IS lateral extension, this difference decreased as the transmurality affection increased. Finally, the infarct reduction exerted by metoprolol was derived from both the transmural and lateral extensions of IS. Conclusions: The transmural and lateral extension of necrosis after myocardial infarction are directly correlated. A proven cardioprotective therapy prevented the necrosis progression in both dimensions. These findings cannot be explained by the classical wavefront theory, suggesting that the necrotic wavefront progresses also in the lateral direction.
Next-generation Sequencing Techniques Brings Novel Identifications of New Genetic Causative Mutations in Pulmonary Arterial Hypertension
Authors: Tamura Yuichi, Kimura Mai, Takei Makoto, Satoh Toru, Fukuda Keiichi, Tatsumi Koichiro, Tanabe Nobuhiro, Kuwana Masataka
Journal: Circulation (2016)
カテプシンB活性化蛍光プローブを用いた腫瘍のin vivo近赤外イメージングと光療法【Powered by NICT】
Authors: Chen Xiaoqiang, Lee Dayoung, Yu Sungsook, Kim Gyoungmi, Lee Songyi, Cho Yejin, Jeong Haengdueng, Nam Ki Taek, Yoon Juyoung
Journal: Biomaterials (2017)
AAV8 Can Induce Innate and Adaptive Immune Response in the Primate Eye
Authors: Felix F. Reichel, Daniyar L. Dauletbekov, Reinhild Klein, Tobias Peters, G. Alex Ochakovski, Immanuel P. Seitz, Barbara Wilhelm, Marius Ueffing, Martin Biel, Bernd Wissinger, Stylianos Michalakis, Karl Ulrich Bartz-Schmidt, M. Dominik Fischer
Journal: Molecular Therapy (2017)
末梢バイパス手術後の血液透析患者における重症下肢虚血の転帰 ステージ4創傷・虚血・足部感染(WIfI)での不良な下肢予後
Authors: Hoshina Katsuyuki, Yamamoto Kota, Miyata Tetsuro, Watanabe Toshiaki
Journal: Circulation (2016)
Olmutinib-induced palmoplantar keratoderma
Authors: K.L. Chen, Y.T. Cho, C.W. Yang, Y.S. Sheen, C.W. Liang, M.E. Lacouture, C.Y. Chu
Journal: British Journal of Dermatology (2017)

olmutinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC), especially for those harboring T790M mutations, the most common reason for other EGFR-TKI resistance. We describe three patients who developed acquired palmoplantar keratoderma (PPK) after taking olmutinib, an adverse event which has not been reported in previous generations of EGFR-TKIs.

This article is protected by copyright. All rights reserved.